Saturday, September 14, 2024 2:32:03 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent RYTM News
- Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 • GlobeNewswire Inc. • 04/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 07:06:53 PM
- Rhythm Pharmaceuticals Announces Changes to Board of Directors • GlobeNewswire Inc. • 04/03/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:16 PM
- Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment • GlobeNewswire Inc. • 03/26/2026 01:01:56 PM
- PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) • PR Newswire (US) • 03/20/2026 04:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 01:20:12 PM
- Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity • GlobeNewswire Inc. • 03/19/2026 10:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:30:21 PM
- Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial • GlobeNewswire Inc. • 03/16/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 11:01:48 AM
- Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity • GlobeNewswire Inc. • 03/01/2026 05:30:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/26/2026 10:37:52 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/26/2026 10:16:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 10:02:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:30:14 PM
- Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:22 PM
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 • GlobeNewswire Inc. • 02/17/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 10:53:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 10:50:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 10:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 10:47:38 PM
- Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit • GlobeNewswire Inc. • 02/05/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:38:11 PM

